Could a common drug stop a rare liver disease from returning after transplant?
NCT ID NCT06905054
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether taking fenofibrate once daily for three years can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. The trial enrolls adults who had a liver transplant for PSC within the past 1 to 7 years and are at higher risk of recurrence. Participants receive fenofibrate and undergo regular blood tests and special MRI scans to monitor for signs of PSC recurrence, compared to a historical group that did not receive the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drug called fenofibrate, taken once daily for 36 months
- What this could lead to
- If it works, this could offer a way to prevent PSC from returning after a liver transplant, potentially reducing the need for repeat transplants.
- What could go wrong
- This is a Phase 2 trial with only 80 participants, comparing results to a historical control group rather than a placebo, which may limit reliability. Fenofibrate may also cause side effects like muscle pain or liver enzyme changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY STRICTURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we safely skip a Pre-Transplant bile duct scan? a trial tests the limits of simpler donor checks
- New antibody aims to tame rare liver disease
- New study examines artery complications in child liver transplants
- Texts and tools could help liver transplant patients stay on track
- Could a fecal transplant help treat a rare liver disease?
- New drug A3907 tested for rare liver disease, study halted early